Effect of Equivalent Dose of Alfentanil and Sufentanil in Bronchoscopic Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-20

Study Completion Date

2024-12-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The equivalent dose of sufentanil and afentanil combined with laryngeal mask was used for complex bronchoscopy to observe the intraoperative effect and the influence on the recovery of patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Sufentanil Combined With Midazolam in Bronchoscopy Under Conscious Sedation: Retrospective Study

NCT03890094

Bronchoscopy Sedation

COMPLETED

A Study Comparing Two Analgesia/Sedation Regimens, Remifentanil/Propofol Versus Sufentanil/Propofol In Mechanically Ventilated Intensive Care Patients Requiring Analgesia And Sedation.

NCT00421720

Analgesia Sedation

TERMINATED PHASE4

The Effect-site Concentration of Remifentanil Blunting Endotracheal Intubation Responses During Anesthesia Induction With Lidocaine or Sufentanil Combined With Etomidate: A Randomized Controlled Study

NCT07089173

Hemodynamics

RECRUITING NA

the Research of Analgesia and Sedation Effect of Remifentanil on ICU Short Operation

NCT02635802

Critical Illness

UNKNOWN PHASE4

Comparison of Analgesic Effect and Prognosis of Butorphanol and Fentanyl in Patients With Mechanical Ventilation

NCT04315935

Analgesia

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Afentanil is a powerful, fast-acting narcotic analgesic, which can effectively inhibit intubation reflex. Compared with sufentanil, it has a short half-life and is safer, and can be used as the first choice for short surgical analgesics. In this study, by comparing the use of equivalent dose sufentanil and afentanil combined with laryngeal mask for complex bronchoscopy, the intraoperative analgesic effect and the influence on the recovery of patients were observed, and a better anesthesia scheme was provided for tracheoscopy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Effect of Drug

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sufentanil group

The dose of sufentanil group is 0.2μg/kg

Group Type EXPERIMENTAL

Alfentanil

Intervention Type DRUG

alfentanil 10ug/kg is used for anesthesia induction

Alfentanil

The dose of aifentanil group is 10μg/kg

Group Type EXPERIMENTAL

Alfentanil

Intervention Type DRUG

alfentanil 10ug/kg is used for anesthesia induction

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alfentanil

alfentanil 10ug/kg is used for anesthesia induction

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

sufentanil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-80,
* ASA I-III level;
* BMI 18.5\~23.9;

Exclusion Criteria

* Patients with full stomach and high risk of reflux aspiration;
* Allergic to benzodiazepines, opioids, rocuronium bromide;
* Those who have taken sedative, analgesic or antidepressant drugs within 24 hours;
* Pregnant and lactating women;
* severe liver and kidney dysfunction;
* Patients with severe anemia and hypoproteinemia;
* Previous drug use history;
* Recently participated in other clinical studies;
* Patients who cannot cooperate with communication.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No